Fabris F, Casonato A, Randi M L, Schivazappa L, Schiavinato L, Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(4):594-601.
We have investigated platelet survival time in 18 patients suffering from valvular heart disease. Platelet survival was performed using the 75Se-methionine method modified by us. Nine of our eighteen patients underwent surgery for heart valve replacement. Platelet survival time was performed before treatment and six months afterwards with placebo or sulfinpyrazone in a double blind study. Before treatment and surgery, platelet survival time was significantly reduced in patients with a history of embolism (P less than 0.0048). In patients receiving valve replacement, platelet survival time was shortened both in the sulfinpyrazone and placebo groups six months after surgery. Of the nine patients not receiving prostheses and with a thrombotic history, treatment with placebo and sulfinpyrazone resulted in improved platelet survival times.
我们研究了18例瓣膜性心脏病患者的血小板存活时间。血小板存活时间采用我们改良的75硒 - 蛋氨酸法进行测定。我们的18例患者中有9例接受了心脏瓣膜置换手术。在一项双盲研究中，于治疗前及治疗后6个月使用安慰剂或磺吡酮测定血小板存活时间。治疗及手术前，有栓塞病史的患者血小板存活时间显著缩短（P小于0.0048）。接受瓣膜置换的患者，术后6个月磺吡酮组和安慰剂组的血小板存活时间均缩短。在9例未接受假体植入且有血栓形成病史的患者中，安慰剂和磺吡酮治疗均使血小板存活时间得到改善。
